If these encouraging preliminary results will be further confirmed in larger patient population, this approach would potentially become a unique opportunity to non-invasively monitor in vivo CD25 + T-cell trafficking in a wide spectrum of diseases, with particular regard to autoimmune diseases and cancer. Here, IL2RA is linked to autoimmune disease.